廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 道指

    39,760.08
    +477.75 (+1.22%)
     
  • 標普 500

    5,248.49
    +44.91 (+0.86%)
     
  • 納指

    16,399.52
    +83.82 (+0.51%)
     
  • Vix指數

    13.01
    +0.23 (+1.80%)
     
  • 富時100

    7,953.04
    +21.06 (+0.27%)
     
  • 紐約期油

    82.71
    +1.36 (+1.67%)
     
  • 金價

    2,229.50
    +16.80 (+0.76%)
     
  • 美元

    7.8240
    +0.0009 (+0.01%)
     
  • 人民幣

    0.9233
    +0.0001 (+0.01%)
     
  • 日圓

    0.0515
    +0.0000 (+0.02%)
     
  • 歐元

    8.4458
    -0.0233 (-0.28%)
     
  • Bitcoin

    70,401.45
    +302.96 (+0.43%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

  • Raymond James initiated coverage on Seagen Inc (NASDAQ: SGEN) at Outperform with a $220 target price.

  • Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company.

  • The relationship with Merck & Company, Inc. (NYSE: MRK) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable bidder.

  • Related: Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

  • The biggest counterpoint to a potential buyout of Seagen is the cluster of potential patent expiry around 2030. The analysts estimate peak sales of ~$6.7 billion in 2030 but are likely below internal risk-modeled assessments.

  • "Overall, the expected growth of the existing Seagen commercial portfolio, significant optionality of label expansion for key programs such as PADCEV, and general increased interest in the ADC modality post-DestinyBreast-04, will likely support Seagen as a high-interest candidate," notes Raymond James.

  • Price Action: SGEN shares are down 0.15% at $178.40 during the market session on the last check Wednesday.

Latest Ratings for SGEN

Date

Firm

Action

From

To

Feb 2022

JMP Securities

Maintains

Market Outperform

Feb 2022

Morgan Stanley

Maintains

Overweight

Feb 2022

HC Wainwright & Co.

Maintains

Buy

View More Analyst Ratings for SGEN

廣告

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.